Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
The company reported first quarter revenues of $19.4 million, missing Wall Street's estimate of $24.5 million.
Researchers validated 95 percent of structural variants called by PacBio sequencing versus 43 percent with Oxford Nanopore, while Illumina missed thousands.
The US ITC has ruled that Oxford Nanopore's products do not infringe on single-molecule sequencing-related patents held by PacBio.
The company beat the analyst estimates for its top and bottom lines in both the fourth quarter and the full year.
BGI has ordered 10 Sequel systems to meet long-read sequencing demand for bacterial, plant, and animal de novo, transcriptome, and epigenomics sequencing.
Mount Sinai researchers have developed a metagenomic method based on PacBio sequencing that uses methylation patterns to identify species and their associated plasmids.
The firm recently hired Kathy Ordoñez as chief commercial officer, who plans to develop clinical opportunities for the company.
The company's product revenues increased over the prior year period, although total revenues missed analysts' average forecast.
PacBio is refining the CRISPR/Cas9 capture technique with several early- access sites and plans to launch it more broadly in 2018.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.